Before Florence pummeled the East Coast, ultimately killing at least 17 people and causing untold millions in damage, some of the world’s largest pharmaceutical companies wrestled with a major dilemma: Should they suspend operations at manufacturing plants in North Carolina, South Carolina, and Virginia, risking shortages of important drugs and vaccines?
GlaxoSmithKline chose to close a plant that makes asthma inhalers, while Novartis shut down a facility that manufactures oral-dosage generic drugs. Pfizer and Merck, meanwhile, decided to scale back operations at multiple North Carolina facilities, closing some entirely.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
